No Evidence of Gut Microbiota Alteration in Psoriasis Patients Switching to Brodalumab after Loss of TNFα Inhibition Effect
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147745 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Admir Vižlin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden. Hauptthemen laut MEDLINE: Psoriasis, Gastrointestinal Microbiome, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leo Pharma (Denmark).
Abstract (Originalsprache)
Biological agents used to treat severe psoriasis may alter the gut microbiota, though current knowledge is limited. This study examines whether switching from TNFα inhibitors, from which patients had reduced or lost effect, to brodalumab, an IL-17 inhibitor, affects the gut microbiota in patients with psoriasis and how these changes correlate with the clinical variables of psoriasis severity and depressive symptoms. Fecal samples from patients were collected before the treatment switch and 12 weeks after the switch and were analyzed for the microbiota composition using next-generation sequencing targeting the V3–V5 region of the 16S rRNA gene, followed by bioinformatics analysis. No significant changes in overall gut microbiota composition were observed after the treatment switch, although individual variations in the Firmicutes/Bacteroidetes ratio were noted, and no significant correlations with clinical variables were found. These findings suggest that short-term changes in gut microbiota in patients with psoriasis are limited and that dysbiosis may be influenced by the interplay of various microbial populations rather than specific taxa. This study provides a foundation for further research into the effects of biological treatments on the gut microbiota in patients with psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden.
- Department of Dermatology and Venereology, Sahlgrenska University Hospital, Region Västra Götaland, 413 45 Gothenburg, Sweden.
- Eurofins Genomics, 78467 Konstanz, Germany.
ORCID-Profile: Yadhu Kumar, Martin Gillstedt
Förderung
- Leo Pharma (Denmark)
Zitieren
APA
Vižlin, A., Andersch Björkman, Y., Kumar, Y., Göthe, M., Gillstedt, M., & Osmančević, A. (2024). No Evidence of Gut Microbiota Alteration in Psoriasis Patients Switching to Brodalumab after Loss of TNFα Inhibition Effect. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147745
Vancouver
Vižlin A, Andersch Björkman Y, Kumar Y, Göthe M, Gillstedt M, Osmančević A. No Evidence of Gut Microbiota Alteration in Psoriasis Patients Switching to Brodalumab after Loss of TNFα Inhibition Effect. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147745
BibTeX
@article{Vilin2024,
author = {Vižlin, Admir and Andersch Björkman, Ylva and Kumar, Yadhu and Göthe, Maria and Gillstedt, Martin and Osmančević, Amra},
title = {No Evidence of Gut Microbiota Alteration in Psoriasis Patients Switching to Brodalumab after Loss of TNFα Inhibition Effect},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147745}
}
EUVIMED